Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
Feb 13, 2019 - MacroGenics’ Public Offering to Raise Funds for R&D, Marketing Is a Smart Move, Stocks: MGNX,OTCQX:RHHBY,MRK, release date:Feb 13, 2019
Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Feb 12, 2019 - Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
Feb 12, 2019 - Dan Loeb's 13F portfolio value decreased from $12.84B to $6.5B this quarter. The number of positions decreased from 31 to 22.Third Point increased Campbell Soup and Saleforce.com, while dropping Unite
Feb 11, 2019 - Two new Breakout Stocks for Week 7 with better than 10% short-term upside potential.Two Best of the Dow 30 for Week 5 mega-cap selections based on breakout model characteristics are: Merck & Co. and t